Fluorouracil 5760mg / D5W 265mL Qty: 1 265 mL Bag
Lack of Assurance of Sterility: Sterility of product is not assured.
18,003 recalls, newest first
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Lack of Assurance of Sterility: Sterility of product is not assured.
Failed stability specifications:This recall has been initiated due to out of specification results for viscosity.
Failed Stability Specification: out of specification result obtained for the Particle Size Distribution test during stability testing.
Failed Stability Specification: out of specification result obtained for the Particle Size Distribution test during stability testing.
Failed Dissolution Specifications; exceeded specification at the 9 hour time point
Failed Dissolution Specifications; exceeded specification at the 9 hour time point
cGMP Deviations; products being recalled in response to a recall notice from the manufacturer, Wockhardt Limited, following a FDA inspection which noted inadequate investigation of market complaints, resulting in unsuccessful identification of root causes, and the investigation not being expanded to prevent repeat failure
cGMP Deviations; products being recalled in response to a recall notice from the manufacturer, Wockhardt Limited, following a FDA inspection which noted inadequate investigation of market complaints, resulting in unsuccessful identification of root causes, and the investigation not being expanded to prevent repeat failure
Sub-potent Drug; firm's analysis revealed subpotent result for morphine sulfate assay.